Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.41 |
| ▸ | AOC2 | O75106 | 2/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13451999 | 0.84 | FAAH (0.47) | EPHX2DPP8DPP7GNAI3GNAO1 | |
| SCHEMBL22874747 | 0.83 | NPC1 (0.53) | EPHX2GNAI3GNAO1GNAI1ALDH1A1 | |
| SCHEMBL16095148 | 0.82 | EPHX2 (0.43) | EPHX2GNAI3GNAO1GNAI1AOC2 | |
| SCHEMBL12385899 | 0.81 | ALDH1A1 (0.58) | EPHX2ALDH1A1NPC1 | |
| SCHEMBL19249296 | 0.81 | EPHX2 (0.42) | EPHX2DPP8DPP7P2RY12ALDH1A1 | |
| SCHEMBL16478759 | 0.79 | JAK1 (0.40) | EPHX2DPP8DPP7GNAI3GNAO1 | |
| SCHEMBL4487574 | 0.79 | EPHX2 (0.51) | EPHX2GNAI3GNAO1GNAI1ALDH1A1 | |
| SCHEMBL12384790 | 0.79 | CYP2D6 (0.46) | EPHX2AOC2P2RY12ALDH1A1NPC1 | |
| SCHEMBL13629808 | 0.79 | EPHX2 (0.43) | EPHX2P2RY12ALDH1A1NPC1 | |
| SCHEMBL12424494 | 0.78 | KMT2A (0.43) | EPHX2DPP8DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9745305-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2017-08-29 | — | — | US | claimed |
| EP-2970305-B1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS INC (US) | 2017-02-22 | — | — | EP | claimed |
| US-20160009718-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2016-01-14 | — | — | US | claimed |
| US-9745305-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| EP-2970305-B1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS INC (US) | 2017-02-22 | — | — | EP | disclosed |
| EP-2970305-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | Constellation Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20160009718-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2016-01-14 | — | — | US | disclosed |
| WO-2014151142-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009718-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | TET1, TET3, EHMT2 | EPHX2 574/4885DPP8 1366/4885DPP7 1367/4885 |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | EPHX2 669/4885DPP8 4561/4885DPP7 4678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.